Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.57B | 4.71B | 4.12B | 3.47B | 2.70B |
Gross Profit | 366.10M | 399.71M | 334.83M | 276.68M | 186.86M |
EBITDA | -334.60M | -189.21M | -1.53B | -4.45B | -1.11B |
Net Income | -323.74M | -255.77M | -1.37B | -3.74B | -1.04B |
Balance Sheet | |||||
Total Assets | 2.27B | 2.82B | 2.93B | 2.89B | 2.48B |
Cash, Cash Equivalents and Short-Term Investments | 919.77M | 1.13B | 1.53B | 1.61B | 1.67B |
Total Debt | 45.49M | 67.56M | 67.76M | 7.52B | 63.59M |
Total Liabilities | 1.06B | 1.18B | 1.10B | 8.32B | 4.27B |
Stockholders Equity | 1.23B | 1.62B | 1.84B | -5.43B | -1.80B |
Cash Flow | |||||
Free Cash Flow | -70.15M | -139.24M | -193.87M | -643.33M | -206.83M |
Operating Cash Flow | -59.45M | -133.50M | -182.07M | -621.92M | -192.12M |
Investing Cash Flow | -622.00K | -720.81M | 1.03B | -1.02B | 319.62M |
Financing Cash Flow | -184.06M | -120.55M | 81.69M | 559.29M | 1.31B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | HK$5.72B | 25.69 | 11.24% | 1.03% | 11.23% | 20.39% | |
73 Outperform | HK$5.66B | 12.83 | 8.40% | 2.36% | 12.41% | ― | |
67 Neutral | HK$14.01B | 45.76 | 7.40% | 1.06% | 0.67% | -1.75% | |
60 Neutral | HK$18.32B | 5.55 | -4.00% | 3.32% | 9.92% | -18.97% | |
55 Neutral | €5.87B | ― | -10.43% | ― | 36.76% | 42.89% | |
47 Neutral | HK$4.36B | ― | -22.75% | ― | -5.07% | -21.18% | |
41 Neutral | HK$3.82B | ― | -69.97% | ― | ― | 3.30% |
Sipai Health Technology Co., Ltd. has announced that its board of directors will hold a meeting on August 18, 2025, to approve the unaudited interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it could impact the company’s financial strategy and shareholder returns.
Sipai Health Technology Co., Ltd. has announced a change in its Hong Kong branch share registrar and transfer office, effective August 1, 2025, to Tricor Investor Services Limited. This move is significant for the company’s administrative operations and may impact shareholders who need to adjust to the new registrar for share-related transactions.
Sipai Health Technology Co., Ltd. has entered into a subscription agreement with JPM to invest in a wealth management product, specifically a Callable Fixed Coupon Note, with a principal amount of US$30 million and an expected annual return rate of 4.58%. This investment is part of the company’s treasury management strategy to maximize returns on surplus cash, offering better yields and flexibility compared to other products, and is considered beneficial for the company and its shareholders.
Sipai Health Technology Co., Ltd. recently redeemed wealth management products from HSBC amounting to US$23.7 million, with an accrued interest income of approximately US$344,115.87. This transaction, classified as a discloseable transaction under the Listing Rules, will contribute to the company’s general working capital, potentially impacting its financial operations positively.
Sipai Health Technology Co., Ltd. announced that all resolutions proposed at its Annual General Meeting (AGM) held on June 20, 2025, were approved by shareholders. Key resolutions included the adoption of the company’s audited financial statements, re-election of directors, re-appointment of Ernst & Young as auditors, and granting mandates to the board for issuing and repurchasing shares. The successful passing of these resolutions reflects strong shareholder support and positions the company for continued strategic growth and operational efficiency.
Sipai Health Technology Co., Ltd. has announced a supplemental disclosure regarding the disposal of its 51% equity interest in four non-wholly owned subsidiaries. The consideration for the disposal was determined through arm’s length negotiations, taking into account the net asset value and historical performance of the target companies, which have experienced a slight decline. The agreed consideration represents a slight discount to a slight premium over the most recent net asset value, and the directors consider it fair and reasonable, serving the interests of the company and its shareholders.
Sipai Health Technology Co., Ltd. has announced a strategic cooperation framework agreement with Arthur J. Gallagher (Singapore) Pte. Ltd. to jointly develop customized insurance solutions and promote innovation in the health insurance sector. This collaboration aims to integrate Sipai’s customer resources with Gallagher’s product design and reinsurance capabilities, enhancing customer service and driving product upgrades. The agreement, initially set for five years, represents a significant opportunity for both parties to leverage their strengths and achieve mutual benefits, potentially reinforcing Sipai’s market leadership.
Sipai Health Technology Co., Ltd., through its wholly-owned subsidiary Sipai Wisdom, has entered into agreements to sell its entire equity interest in four non-wholly owned subsidiaries to Shengyang Yijiachen and Shenyang Hengruisheng for RMB5,899,786. This transaction will result in the Group ceasing to hold any interest in these subsidiaries, which will no longer be included in its consolidated financial statements. The disposal is classified as a discloseable transaction under the Hong Kong Listing Rules, as it involves a percentage ratio of more than 5% but less than 25%, and does not constitute a connected transaction.
Sipai Health Technology Co., Ltd. has announced its upcoming annual general meeting scheduled for June 20, 2025, in Shanghai. Key agenda items include the adoption of the 2024 financial statements, re-election of directors, re-appointment of Ernst & Young as auditors, and authorizations related to share issuance. These resolutions aim to strengthen the company’s governance and financial oversight, potentially impacting its market positioning and stakeholder confidence.